KI8751 50 mg | 99.73%
TargetMol
KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
More Information Supplier PageKI8751
Search Results
KI8751 25 mg | 99.73%
TargetMol
KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
More Information Supplier PageKI8751
KI8751 10 mg | 99.73%
TargetMol
KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
More Information Supplier PageKI8751
EHop-016 5 mg | 97.69%
TargetMol
EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.
More Information Supplier PageEHop-016
EHop-016 50 mg | 97.69%
TargetMol
EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.
More Information Supplier PageEHop-016
EHop-016 25 mg | 97.69%
TargetMol
EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.
More Information Supplier PageEHop-016
Vortioxetine hydrobromide 10 mg | 99.48%
TargetMol
Vortioxetine (Lu AA21004) is a serotonin (5-HT) modulator and stimulator (SMS), inhibits 5-HT1A/1B/3A/7 receptor and SERT (IC50: 15/33/3.7/19/1.6 nM).
More Information Supplier PageVortioxetine hydrobromide
Dapagliflozin 5 mg | 99.74%
TargetMol
Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.
More Information Supplier PageDapagliflozin
Dapagliflozin 50 mg | 99.74%
TargetMol
Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.
More Information Supplier PageDapagliflozin
Dapagliflozin 10 mg | 99.74%
TargetMol
Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.
More Information Supplier PageDapagliflozin